

Pomalidomide capsule (POMALYST)

Criteria for Use

January 2025

VA Pharmacy Benefits Management Services and National Formulary Committee

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National Formulary Committee Monograph on this drug at the [PBM INTRAnet](#) site for further information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive pomalidomide.

- Absolute neutrophil count (ANC) < 500/mm³
- Hemoglobin < 8 g/dL; Must transfuse to hemoglobin above 8 gm/dL prior to therapy initiation
- Platelet count < 50,000/mm³
- Eastern Cooperative Oncology Group performance status > 2
- Patient has not been screened for Hepatitis B Virus
- Active or uncontrolled infection
- Known pregnancy
- Lactating

Inclusion Criteria

One of the following criteria must be met.

- Relapsed or refractory multiple myeloma, following at least 2 lines of therapy that included lenalidomide and a proteasome inhibitor
- Diagnosis of Kaposi sarcoma

Additional Inclusion Criteria

All of the following criteria must be met.

- Care is provided by a VA or VA Community Care hematology/oncology provider
- Goals of care and role of Palliative Care consult have been discussed and documented
- Venous thromboembolism (VTE) risk scoring (i.e. SAVED, IMPEDE) performed for consideration of VTE prophylaxis

Additional Inclusion Criteria

If applicable.

- Patients who can become pregnant and patients with partners who can become pregnant must comply with pregnancy testing and contraception requirements for pomalidomide under the POMALYST REMS program

Other Justification

- _____